Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference
Zynerba Pharmaceuticals (Nasdaq: ZYNE) will participate in the 33rd Annual ROTH Conference from March 15-17, 2021. The virtual event aims to connect the Company’s management with investors. Interested investors can arrange meetings on March 17 by contacting the ROTH conference coordinator or via the provided email address.
Zynerba focuses on transdermal cannabinoid therapies for rare neuropsychiatric disorders, including Fragile X syndrome and autism spectrum disorder. The Company is committed to improving the lives of patients with severe health conditions.
- None.
- None.
DEVON, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in the 33rd Annual ROTH Conference, which will be held virtually on March 15-17, 2021.
Investors interested in arranging a virtual meeting with the Company’s management on Wednesday, March 17, should contact the ROTH conference coordinator or brandon.weiner@westwicke.com.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Contact
Peter Vozzo
Westwicke, an ICR Company
Office: 443-213-0505
Cell: 443-377-4767
peter.vozzo@westwicke.com
FAQ
When is Zynerba Pharmaceuticals participating in the ROTH Conference?
How can investors meet Zynerba Pharmaceuticals' management during the conference?
What are the key focus areas of Zynerba Pharmaceuticals?
What is the stock symbol for Zynerba Pharmaceuticals?
Where can I find more information about Zynerba Pharmaceuticals?
